BioNTech's Oncology Pipeline Faces ASCO Scrutiny as Cash-Powered Stock Struggles to Regain Footing

BioNTech shares trade 8% below key moving average as ASCO presentations on pumitamig, gotistobart, and ADCs offer potential catalyst; firm holds €16.8B cash despite declining COVID revenue.

BioNTech heads into a shortened trading week with its stock trading nearly a tenth below its 200-day moving average — a stark reminder that the market remains unconvinced despite a €16.8 billion cash pile and an ambitious oncology pipeline. The shares closed Friday at €79.50, up 1.53% on the day but down 15.25% over the past month. That 8.06% discount to the long-term trend line underscores how much ground needs to be recovered before investor sentiment shifts.

The trigger for a potential reversal arrives at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, running from May 29 to June 2. BioNTech has scheduled two oral presentations and four "Trial in Progress" posters, covering a range of programs across lung cancer, gynaecological tumours, prostate cancer and other solid malignancies. The sheer breadth of the pipeline is the message: the company now has more than 25 Phase 2 and Phase 3 clinical studies underway, of which 13 are registrational.

Among the most closely watched data sets are those for pumitamig, a bispecific immunomodulator being tested in the ROSETTA-Lung-02 trial. BioNTech will present interim results from the first-line non-small cell lung cancer study, which has already triggered a Phase 3 component. This marks the third global data readout to show encouraging anti-tumour activity in combination with chemotherapy, according to the company. Across the hall, gotistobart — a CTLA-4 antibody — will take centre stage with Phase 2 overall survival data in platinum-resistant ovarian cancer, a notoriously difficult indication where a chemotherapy-free option would be a significant advance.

The ADC programmes add further depth. On May 30, BNT326/YL202 (a HER3-ADC) will be featured as a monotherapy and in combination with a bispecific anti-PD-L1-x-VEGF antibody in advanced solid tumours. The following day, BNT324/DB-1311 (a B7H3-ADC) enters a Phase 3 showdown against docetaxel in metastatic castration-resistant prostate cancer. June 1 sees trastuzumab pamirtecan (a HER2-ADC) in a Phase 3 study for pretreated HER2-expressing recurrent endometrial carcinoma.

All this clinical firepower comes at a time when BioNTech's revenue base has shrunk dramatically. First-quarter sales totalled just €118.1 million, compared with €182.8 million a year earlier, as Covid vaccine demand wanes. The net loss reached €531.9 million, with research and development expenses of €557.0 million largely driven by immuno-oncology and ADC work. Yet the cash position remains formidable: €16.8 billion in liquidity, cash equivalents and marketable securities. On May 7, the board authorised a $1.0 billion American Depositary Share buyback programme, open until May 6, 2027 and contingent on market conditions.

Beyond the clinical calendar, macro data will test investor risk appetite. US consumer confidence figures land on May 26, followed by the revised GDP reading and income-and-spending data including the PCE inflation gauge on May 28. For a development-stage biotech stock, interest rate expectations and overall market mood can be as influential as clinical endpoints.

The ASCO presentations serve as BioNTech's most concrete near-term catalyst. If the data validate multiple development paths — across lung cancer, gynaecological cancers, prostate cancer and solid tumours — the oncology narrative will gain credibility. Until then, the €79–€80 zone remains the immediate reference point for whether the stock is truly stabilising or simply pausing before the next leg lower.